<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35177827</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-5365</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>57</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Bone marrow transplantation</Title>
          <ISOAbbreviation>Bone Marrow Transplant</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Early vascular toxicity after pediatric allogeneic hematopoietic stem cell transplantation.</ArticleTitle>
        <Pagination>
          <StartPage>705</StartPage>
          <EndPage>711</EndPage>
          <MedlinePgn>705-711</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41409-022-01607-8</ELocationID>
        <Abstract>
          <AbstractText>Treatment-related mortality and morbidity remain a challenge in hematopoietic stem cell transplantation (HSCT). In this retrospective, single-center study, we analyzed endothelial damage as a potential, common denominator and mechanism for the adverse effects. We evaluated the prevalence of key vascular complications and graft-versus-host disease among 122 pediatric patients with an allogeneic HSCT between 2001 and 2013. The spectrum and frequency of acute adverse events emerging ≤100 days post transplant were graded according to the CTCAE 4.03 and analyzed. We identified a total of 19/122 (15.6%) patients with vascular complications, fulfilling the criteria of capillary leak syndrome, veno-occlusive disease/sinusoidal obstruction syndrome or thrombotic microangiopathy. The patients had a poorer overall survival (77% versus 26%, p &lt; 0.001). Nearly one half (56/122, 45.9%) had at least one, severe (grade 3 or 4) adverse event. Patients with vascular complications had more often edema/effusions (p = 0.023), thrombocytopenia (p = 0.001), gastrointestinal bleeding (p &lt; 0.001), acute kidney injury (p &lt; 0.001), ascites (p &lt; 0.001) or bilirubin increase (p = 0.027). These endotheliopathy-related adverse events appeared early post HSCT, varied in their clinical phenotype and predicted a poor outcome. An unrelated donor but not previous exposure to leukemia or irradiation-based conditioning was identified as a risk factor for vascular complications and endotheliopathy.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Leimi</LastName>
            <ForeName>Lilli</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0002-0774-7110</Identifier>
            <AffiliationInfo>
              <Affiliation>University of Helsinki, Helsinki University Hospital, Children's Hospital, and Pediatric Research Center, Helsinki, Finland. lilli.leimi@helsinki.fi.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jahnukainen</LastName>
            <ForeName>Kirsi</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>University of Helsinki, Helsinki University Hospital, Children's Hospital, and Pediatric Research Center, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>NORDFERTIL Research Lab Stockholm, Department of Women's and Children's Health, Karolinska Institutet and University Hospital, Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Olkinuora</LastName>
            <ForeName>Helena</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>University of Helsinki, Helsinki University Hospital, Children's Hospital, and Pediatric Research Center, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Meri</LastName>
            <ForeName>Seppo</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Bacteriology and Immunology and Translational Immunology Research Program, University of Helsinki, and Diagnostic Center, Helsinki University Hospital, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vettenranta</LastName>
            <ForeName>Kim</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>University of Helsinki, Helsinki University Hospital, Children's Hospital, and Pediatric Research Center, Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Bone Marrow Transplant</MedlineTA>
        <NlmUniqueID>8702459</NlmUniqueID>
        <ISSNLinking>0268-3369</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006086" MajorTopicYN="Y">Graft vs Host Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006504" MajorTopicYN="Y">Hepatic Veno-Occlusive Disease</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057049" MajorTopicYN="Y">Thrombotic Microangiopathies</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019172" MajorTopicYN="N">Transplantation Conditioning</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>18</Day>
          <Hour>5</Hour>
          <Minute>44</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35177827</ArticleId>
        <ArticleId IdType="pmc">PMC9090633</ArticleId>
        <ArticleId IdType="doi">10.1038/s41409-022-01607-8</ArticleId>
        <ArticleId IdType="pii">10.1038/s41409-022-01607-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101. doi: 10.1056/NEJMoa1004383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1004383</ArticleId>
            <ArticleId IdType="pmc">PMC3017343</ArticleId>
            <ArticleId IdType="pubmed">21105791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brissot E, Rialland F, Cahu X, Strullu M, Corradini N, Thomas C, et al.  Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution. Bone Marrow Transplant. 2016;51:267–72. doi: 10.1038/bmt.2015.250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bmt.2015.250</ArticleId>
            <ArticleId IdType="pubmed">26642337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mateos MK, O’Brien TA, Oswald C, Gabriel M, Ziegler DS, Cohn RJ, et al.  Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review. Pediatr Blood Cancer. 2013;60:1520–7. doi: 10.1002/pbc.24559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.24559</ArticleId>
            <ArticleId IdType="pmc">PMC3798104</ArticleId>
            <ArticleId IdType="pubmed">23733511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, et al.  Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant. 2017;52:1399–405. doi: 10.1038/bmt.2017.119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bmt.2017.119</ArticleId>
            <ArticleId IdType="pubmed">28650448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A, et al.  Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood. 2011;118:1685–92. doi: 10.1182/blood-2011-02-334821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-02-334821</ArticleId>
            <ArticleId IdType="pubmed">21636856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dalle JH, Giralt SA. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transplant. 2016;22:400–9. doi: 10.1016/j.bbmt.2015.09.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbmt.2015.09.024</ArticleId>
            <ArticleId IdType="pubmed">26431626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al.  Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124:645–53. doi: 10.1182/blood-2014-03-564997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-03-564997</ArticleId>
            <ArticleId IdType="pmc">PMC4110664</ArticleId>
            <ArticleId IdType="pubmed">24876561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jodele S, Dandoy CE, Myers KC, El-Bietar J, Nelson A, Wallace G, et al.  New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Transfus Apheresis Sci. 2016;54:181–90. doi: 10.1016/j.transci.2016.04.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.transci.2016.04.007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011;46:1495–502. doi: 10.1038/bmt.2011.65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bmt.2011.65</ArticleId>
            <ArticleId IdType="pubmed">21460864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucchini G, Willasch AM, Daniel J, Soerensen J, Jarisch A, Bakhtiar S, et al.  Epidemiology, risk factors, and prognosis of capillary leak syndrome in pediatric recipients of stem cell transplants: a retrospective single-center cohort study. Pediatr Transplant. 2016;20:1132–6. doi: 10.1111/petr.12831.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/petr.12831</ArticleId>
            <ArticleId IdType="pubmed">27734564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al.  Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571–5. doi: 10.1016/j.bbmt.2005.06.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbmt.2005.06.001</ArticleId>
            <ArticleId IdType="pubmed">16041306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Söderhäll S, et al.  Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24:345–54. doi: 10.1038/leu.2009.251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2009.251</ArticleId>
            <ArticleId IdType="pubmed">20010622</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, et al.  Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606–15. doi: 10.1038/leu.2017.265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2017.265</ArticleId>
            <ArticleId IdType="pubmed">28819280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, et al.  Long-term results in children with AML: NOPHO-AML Study Group – report of three consecutive trials. Leukemia. 2005;19:2090–100. doi: 10.1038/sj.leu.2403962.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.leu.2403962</ArticleId>
            <ArticleId IdType="pubmed">16304571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, Jónsson ÓG, Lausen B, et al.  Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29:310–5. doi: 10.1200/JCO.2010.30.6829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.30.6829</ArticleId>
            <ArticleId IdType="pubmed">21149663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava D, Leisenring WM, et al.  The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014;61:53–67. doi: 10.1002/pbc.24679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.24679</ArticleId>
            <ArticleId IdType="pmc">PMC3933293</ArticleId>
            <ArticleId IdType="pubmed">23940101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al.  Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics. 2008;121:387–96. doi: 10.1542/peds.2007-0575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2007-0575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304. doi: 10.1097/00007890-197410000-00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00007890-197410000-00001</ArticleId>
            <ArticleId IdType="pubmed">4153799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cho BS, Yahng SA, Lee SE, Eom KS, Kim YJ, Kim HJ, et al.  Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;90:918–26. doi: 10.1097/TP.0b013e3181f24e8d.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/TP.0b013e3181f24e8d</ArticleId>
            <ArticleId IdType="pubmed">20717073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle JH, et al.  Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transplant. 2018;53:138–45. doi: 10.1038/bmt.2017.161.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bmt.2017.161</ArticleId>
            <ArticleId IdType="pmc">PMC5803572</ArticleId>
            <ArticleId IdType="pubmed">28759025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M, et al.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv. 2019;3:2424–35. doi: 10.1182/bloodadvances.2019000143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2019000143</ArticleId>
            <ArticleId IdType="pmc">PMC6693000</ArticleId>
            <ArticleId IdType="pubmed">31409584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nava T, Ansari M, Dalle JH, de Heredia CD, Güngör T, Trigoso E, et al.  Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant. 2020;55:1126–36. doi: 10.1038/s41409-020-0818-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41409-020-0818-4</ArticleId>
            <ArticleId IdType="pubmed">32029909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batts ED, Lazarus HM. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant. 2007;40:709–19. doi: 10.1038/sj.bmt.1705758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bmt.1705758</ArticleId>
            <ArticleId IdType="pubmed">17603513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willems E, Baron F, Seidel L, Frere P, Fillet G, Beguin Y. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplant. 2010;45:689–93. doi: 10.1038/bmt.2009.230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bmt.2009.230</ArticleId>
            <ArticleId IdType="pubmed">19718063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gavriilaki E, Sakellari I, Anagnostopoulos A, Brodsky RA. Transplant-associated thrombotic microangiopathy: opening Pandora’s box. Bone marrow Transplant. 2017;52:1355–60. doi: 10.1038/bmt.2017.39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bmt.2017.39</ArticleId>
            <ArticleId IdType="pubmed">28287636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamae H, Yamane T, Hasegawa T, Nakamae M, Terada Y, Hagihara K, et al.  Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2006;81:525–31. doi: 10.1002/ajh.20648.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.20648</ArticleId>
            <ArticleId IdType="pubmed">16755559</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenthal J. Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment. J Blood Med. 2016;7:181–6. doi: 10.2147/JBM.S102235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/JBM.S102235</ArticleId>
            <ArticleId IdType="pmc">PMC5015877</ArticleId>
            <ArticleId IdType="pubmed">27621680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, et al.  The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2016;127:989–96. doi: 10.1182/blood-2015-08-663435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2015-08-663435</ArticleId>
            <ArticleId IdType="pmc">PMC4828073</ArticleId>
            <ArticleId IdType="pubmed">26603840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al.  Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122:2003–7. doi: 10.1182/blood-2013-05-501445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2013-05-501445</ArticleId>
            <ArticleId IdType="pmc">PMC3790943</ArticleId>
            <ArticleId IdType="pubmed">23814021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elsallabi O, Bhatt VR, Dhakal P, Foster KW, Tendulkar KK. Hematopoietic stem cell transplant-associated thrombotic microangiopathy. Clin Appl Thrombosis/Hemost. 2016;22:12–20. doi: 10.1177/1076029615598221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1076029615598221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, et al.  A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015;29:191–204. doi: 10.1016/j.blre.2014.11.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.blre.2014.11.001</ArticleId>
            <ArticleId IdType="pmc">PMC4659438</ArticleId>
            <ArticleId IdType="pubmed">25483393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willems E, Baron F, Seidel L, Frère P, Fillet G, Beguin Y. Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplant. 2010;45:689–93. doi: 10.1038/bmt.2009.230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bmt.2009.230</ArticleId>
            <ArticleId IdType="pubmed">19718063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakellari I, Gavriilaki E, Boussiou Z, Batsis I, Mallouri D, Constantinou V, et al.  Transplant-associated thrombotic microangiopathy: an unresolved complication of unrelated allogeneic transplant for hematologic diseases. Hematological Oncol. 2017;35:932–4. doi: 10.1002/hon.2346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hon.2346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooke KR, Jannin A, Ho V. The contribution of endothelial activation and injury to end-organ toxicity following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:23–32. doi: 10.1016/j.bbmt.2007.10.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbmt.2007.10.008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li A, Wu Q, Davis C, Kirtane KS, Pham PD, Sorror ML, et al.  Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal. Biol Blood Marrow Transplant. 2019;25:570–6. doi: 10.1016/j.bbmt.2018.10.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbmt.2018.10.015</ArticleId>
            <ArticleId IdType="pmc">PMC6450411</ArticleId>
            <ArticleId IdType="pubmed">30940363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dandoy CE, Rotz S, Alonso PB, Klunk A, Desmond C, Huber J, et al.  A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Adv. 2020;5:1–11. doi: 10.1182/bloodadvances.2020003455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2020003455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierik E, Prins JR, van Goor H, Dekker GA, Daha MR, Seelen MAJ, et al.  Dysregulation of complement activation and placental dysfunction: a potential target to treat preeclampsia? Front Immunol. 2020;10:3098. doi: 10.3389/fimmu.2019.03098.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.03098</ArticleId>
            <ArticleId IdType="pmc">PMC6974484</ArticleId>
            <ArticleId IdType="pubmed">32010144</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
